Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 723

Ferroportin Nucleic Acids, Proteins and Antibodies

Inventors: Leonard Zon, Adriana Donovan

Invention Types: Diagnostic/Prognostic, Therapeutics

Research Areas: Cardiovascular/Cardiology, Immunology, Metabolic Disease, Oncology/Hematology

Keywords: Antibody, Composition of Matter, Gene, Protein

For More Information Contact:  Meyer, Abbie

 

Invention Description:

Altered iron metabolism is linked to the pathology of many diseases, such as hemachromatosis and anemias associated with chronic disease. The zebrafish weissherbst gene was identified by positional cloning from mutant zebrafish with congenital anemia. The gene was shown to express a novel protein, ferroportin, that localizes to the membrane of the yolksac and functions as an iron transporter. Mammalian homologues were isolated, and ferroportin expression was demonstrated in enterocytes of the duodenum, and in the spleen, liver, placenta, brain and macrophages. Ferroportin as been demonstrated to be the major transporter of iron egress out of cells, and is crucial for release of iron into the circulation from absorption in the digestive tract and for release of iron scavenged from hemogloblin during red blood cell turnover. Ferroportin is the target of hepcidin, the master regulator of iron hemostasis, so it is a key target for systemic regulation of iron availability.

Applications:

Issued US patents 7,166,448 and 7,521,055 and pending continuations claim mammalian ferroportin nucleic acids, proteins and antibodies, which have application in diagnostics and therapeutics for a wide range of disorders of iron homeostasis.

Competitive Advantages:

Disorders of iron metabolism include hemochromatosis and anemias, including anemia of chronic disease associated with various conditions including malignancies and response to chemotherapy, autoimmune dsiorders, leukemias, inflammation and infections. Ferroportin nucleic acid are crucial to the detection of genetic and gene espression alterations in iron metabolism disorders. Anti-ferroportin antibodies offer promise for therapeutic intervention in iron homeostasis.

Business Opportunity:

Exclusive License

Key Publications: A. Donovan, A. Brownlie, Y. Zhou, J. Shepard, S. Pratt, J. Moynihan, B. Paw, A. Drejer, B. Barut, A. Zapata, T. Law, C. Brungara, S. Lux, G. Pinkus, J. Pinkus, P. Kingsley, J. Palis, M. Fleming, N. Andrews, LI. ZON. et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403, 776 - 781 (2000).

IPStatus: Patented